solid the is scientific certepetide major to preclinical tumors. environment Lisata's of works. the the fundamental rationale afternoon, is to an Lasker growing discoveries which platform programs that cancer increasing This are pressures. based those, the vast of pharmacoeconomic in everyone. A address from especially clinical sound relevant include Dr. advanced and on James, development technology. Ruoslahti works Thanks, These led being early platform designed good CendR Erkki impediments spawned prize published to a our and prevalence of treatment body awarded CendR of product and for successful
Our is have clinical product that the optimized generate unambiguous they're data. to end with registration and designed rigorously in been meaningful studies clinically mind
phased studies many unlike in authorities appropriately by are trials. and similarly are regulatory such, studies, sized of placebo-controlled, endpoints our pivotal As primary employ preferred that support
and clear evaluate trials practices strategic approach, current efficiently effect generate consumption is our fit for design combination This at data of of our but not avoid standards last methodology choices treatment as the treatment expensive do as do they rigorous keeping clinical to possible. care on sites. allow Further, always the with are capital the certepetide with current to least experiment and us in become that to rapidly could clinically most meaningful the and scientifically which in with work discernment to unnecessary. mantra These by first time afford diluent
ASCEND the have strategy a initial excited we'll we special We aforementioned at a underpin the end reviews designations, that Xb year why implemented more and moment. also accelerated of commercialization. our approvals. from line and company's priority the speak that devised strategy will regulatory includes top Phase opportunities I certepetide's can optimizes as But trial. report large imagine, obtaining results about are in the regulatory so the you future review regulatory This and strategy to
other the especially to some and specifics of However, tumor. for the get me advances to outcomes of Cancers, poor many cancer patients. clinical stroma, background, of and solid access actually cancer, to important before with which associated tissue in multiforme by listening who pharmacotherapies first as still dense those glioblastoma fibrotic immunotherapies, are studies, allow surrounded as such me tumors the provide for CAR-T tumors time. each a limits gastric known solid I are cancer cancer, therapy therapy, most for or brain the including the Despite to are pancreatic cell
a with solid patient's suppresses addition, effective tumors TME, makes in system microenvironment, cancer. or which In immune a many less hostile tumor also it and fighting present
therapies many the combination effective the are hostile these and stroma anti-cancer prevents solid from being targeting the This, that and tumors. most the cancer efficient optimally not tissue, treatment the The coupled of immunotherapies major effectiveness treating maximizing with of in dense safety cancers. only defines chemotherapies challenge fact in of TME and in
combat active CN rule system. to the exploit to and stroma It's this, system occurring the the drugs approach activate active into Cend transport transport a to naturally tumor. However, the to is through selectively Lisata's deliver anticancer
endothelial Certepetide v alpha cells another X but through binds CendR-active high peptide mechanism, fragment. Upon on vascular CendR amino association of of actuates by microvesicles with fragment to is peptides, or is tumor nearby which beta and receptor X it the into amino cyclic the occurring integrins, tissue. the integrin called naturally from receptors, microvesicles certepetide neuropilin-X manifested any the [indiscernible] surface the which The one for is integrin cyclic X peptide in microenvironment. Once a and cells acid proteases is healthy which a bound linear proteases these upregulated tumor not CendR binding acid tumor peptide on specificity betaX certepetide are a converts significantly into and X linear fragments vasculature it is on the co-administered Once them cleaved the affinity transport formation and activated, neuropilin-X cell. by from the same of the including receptor, These the and anticancer of at stroma ferries system, cells. the in moieties encapsulate essentially tumor. drugs, certepetide circulatory CendR and in
companion the can drug action therapies, of Certepetide's which or agnostic RNA-based it anticancer anticancer and emerging combined it's the chemotherapies, of existing with a immunotherapies modality and be therapies. mechanism is with administered, wide range of to including
research XXX the These shown and in action. resistance been more impeding certepetide it making the collaborators microenvironment, publications the to medications reported, Additionally, actually around Lisata modify come from certepetide mechanism reducing world range tumor scientific and models and cells, sponsored has anticancer subject studies of as has of of less to metastatic than and from the to preclinical preventing previously results into been relevant hostile cascade. to a groups tumor immune
including nonclinical and and date, collaborators, cell tolerability to enhance standard-of-care range RNA-based to pancreatic demonstrating modalities, with significant demonstrated with data, of chemotherapy our a cancer. clinical Along safety, also delivery patients anticancer of therapies. therapy metastatic therapeutics amassed activity delivery immunotherapies, favorable has enhanced And we've even certepetide chemotherapies, for of
our has of be in seen of As strategy. can number regulatory to our the awarded designations fruits mentioned earlier, The optimize labor regulatory special Lisata diligently to our product. worked
for relevant be early track us recipient affords Certepetide is an if review. designation accelerated fast for criteria frequent priority FDA and a by example, submit met. NDA For the our will and are which the the also ability to more review for certepetide FDA, interactions the eligible the with rolling of components approval
multiple certepetide for the in glioma the XXXX, designation Lisata of United pancreatic and fees Europe States. orphan in well as certepetide malignant also Further, since designation rare has market user one from for one exemption including provides cancer start the pediatric and orphan exclusivity. has extended for a States. disease Orphan and U.S. received And in affords osteosarcoma an both received designations, the designation as United
rare for or background, of under rare new for drug cases application disease substantial diseases ticket United years XX the as diseases review a primarily of indication in than defines Just golden designation. the pediatric age. is with referred States FDA and receipt a once FDA or priority as often life-threatening affect of individuals NDA product XXX,XXX to and a that the designation are the the having serious pediatric the received voucher, benefit fewer A approves
more product standard be or XX by months. sponsor rapid between valuable XXX of a the or various especially the compel for their is of of X sold sold are much Vouchers to voucher NDA they sponsor use. or million clinical certepetide's review have for strategy an and the anticancer includes of ductal for for a biologic another used as sold adenocarcinoma additional to pancreatic enhance to solid ability for of dozen priority treatment may globally as a can in recently, approximately a active Overall, of USD another months review a subject have and certepetide end, vouchers to time pursuit application be solid this historically nearly license certepetide indication tumors. the a of review reducing The alongside used studies, metastatic which currently for treatments as our trials planned million. for $XXX tumors.
To million development variety exploits the further treatment registration range of $XX Priority
with at ASCEND with patient New the XXX in combination nab-paclitaxel metastatic the The University evaluating trial conducted collaboration of care, double-blind, randomized patients trial and chemotherapy Cancer XX sites often trial, in certepetide is trial, the the ductal Australia or AGITG being For Australasian by at adenocarcinoma, Trials in standard Group, mPDAC. Zealand, gemcitabine clinical and of as known NHMRC center Gastrointestinal led Sydney. with clinical in placebo-controlled example, pancreatic it's
study received standard single per kilogram milligram B to X.X the dose after is Cohort dose second of kilogram certepetide, simultaneously first. certepetide, a care, A, The the X.X identical hours X cohorts. of with Cohort X but while of A with per of consists essentially Cohort milligram given
As be which interim completed we XXXX previously patients be study modification. planned With quarter recommended the XXX futility fourth year line data in set of by expect XX the reported the assigned A study from top Committee, a analysis of fourth available the complete in positive all independent without reported by trial of the data mid-XX. outcome to from to Cohort study and to the patients was of this the XXXX, from announced Monitoring Data of enrollment Safety study's continuation quarter in the
have and of The the prospect encouraging, data steps. planning positive we subsequent begun development is
For Goods a which government believe of Administration, of of application of the agency therapeutic approval. that the is opinion the TGA, they provisional from for example, Australian or version we've data medicine already goods Therapeutic warrant an the submission from Cohort determination, and received A ASCEND regulatory positive an conditional Australian
with are data EMA expect hand. in the We once discussions FDA similar and
study have once support The program and data that anticipated and designed We full X Phase X proposed approval the mPDAC. a and this already optimize inform registration the maintain be clinical to in completed. Phase year necessary required conditional further will our anticipated will ASCEND
neck originally designed care our squamous States, second-line The certepetide trial multicenter arm basket care trial double-blind cell of in Phase BOLSTER evaluating Phase squamous trial, and esophageal in first-line with Next, BOLSTER evaluating as placebo-controlled randomized X combination a United the BOLSTER in cholangiocarcinoma. and carcinoma, was with the of is carcinoma cell in second-line The combination cholangiocarcinoma. standard trial. X, standards trial Xa certepetide head for first-line
to head for with During months to adding in formularies. challenges to neck not activities consistent arms country-specific access care the cohort, of esophageal of recruit study X standard however, were drugs and planning drugs national delays deemed these feasible these and we initiation and care that of standard given and
and were Given to these originally arms obstacles, much X to longer projected. significantly costly than take be more going the complete
to the fiscally terminate took arms. but we result, a As decision these responsible nevertheless, difficult
action, that refocused Following strategically on trial the first-line cholangiocarcinoma we the arm.
progress team expectations. to it actually this, made that significant relates to far As that date internal I'm has delighted has report to exceeded enrollment Lisata's
cholangiocarcinoma of of substantially along the sooner. this easily to expect not initiating the amendment To treatment cholangiocarcinoma. this, with the effectiveness of by the corresponding months. the year, us end FDA We network the coming complete and with patients efficiency provide and for we consider news weeks for to if enrollment involved their requiring first-line Also, the investigators active has in a investigator sites in prompted are the arm, first-line we'll enthusiasm our discussions second-line more BOLSTER the study in on in achieve and and cholangiocarcinoma
United States to cancers, trial end a FOLFIRINOX therapies in the the it in pancreatic, X progress appendiceal completion make the based all It's enrollment of colon with open-label for and combination with Phase neoadjuvant expected this is of and for combination arms year us continues by certepetide with CENDIFOX certepetide in China Xb/Xa Next steady profiling XXXX. study. data. long-term license also trial posttreatment Pharmaceutical, biopsy nab-paclitaxel and territory evaluating This of treatment pre- as the in well with mPDAC. Greater certepetide a currently heart data will and immuno is outcome as provide the Qilu as gemcitabine in
findings Xb/Xa Qilu pancreatic Australia conducted ASCO sharing previously from which the and trial the data in the gemcitabine Pharmaceutical preliminary plus During corroborated of presented an XXXX Annual with cancer. abstract patients in metastatic Phase nab-paclitaxel from trial, certepetide Meeting, reported
who Xb/Xa of this from as efficacy Upon in Phase in take durvalumab patient FOLFIRINOX completion subject placebo-controlled, a nonresectable begun adenocarcinoma, safety, placebo-controlled study which a complete certepetide locally Phase half funding planned our when of has partner, standard adenocarcinoma surgically. regimen, FOLFIRINOX the only second mPDAC. care in Journal, versus study, X with months patients data is in of in proof-of-concept published Xb/Xa expected treatment of gastroesophageal radiographically first-line comes and and safety The efficacy reporting. details initially treating existing X complete of certepetide WARPNINE. As XX recently advanced standard trial and study achieved funding patient announced, iLSTA cohort to locally PDAC. of addition combination versus and reports months care months the their to XX for single-center analysis with certepetide standard recently the with combination subsequent for is confirmed and cancer our response. care the achieved collaboration nivolumab nonresectable with in of response trial Enrollment and the the patients given randomized, of This In approximately another Phase with partner, and case in therapeutic subject and oncology a complete pending with single-blind, both plus enrollment of gemcitabine early in is initiation The certepetide is chemotherapy gastroesophageal pembrolizumab. and follow-up Qilu accrual inspiration combination underwent plus by evaluating care function inhibitor, XXXX.
iGoLSTA, in evaluating The study care the certepetide pharmacodynamic alone in partial a combination and alone Australia. availability of in standard standard as metastatic care nab-paclitaxel with findings a is a checkpoint to standard trial advanced achieved a of treatments response WARPNINE, a
glioblastoma alone in as response Xa the is with X:X standard matching Phase GBM, and initiated hope to February already of in enrolling with certepetide study plus with evaluating diagnosed related enrolled patients This temozolomide Remarkably in study double-blind or being Latvia is of iGoLSTA certepetide of targeted added conducted across We patients multiform has of patients the care in standard care placebo-controlled in an enroll study multiple timing temozolomide care. study on XX proof-of-concept certepetide versus a A been and Estonia thankfully, is the several of designed and subject update randomized XXXX. treated. to when This quarters. temozolomide and of remains newly a randomization to coming the achieving multiform. healthy plus with of combination to standard versus in placebo provide since the actively study complete certepetide and glioblastoma execution sites placebo
On we're general trials additional top strategy. of exploring previously supporting the our development studies, described
starting data remain executed in that funded only of trials be within trials that we steadfast time. However, can can period through be to a and reasonable
around Finally, although I And I I studies, Lisata would remiss are and timelines didn't if change. thus, be limited several grateful the in studies running we to to confidence you in participating world. mentioned remind of to subject have great may that and patients has extremely said, control clinical investigators That be investigators trials trials. are our investigator-initiated these the certepetide we and especially the the expectations
a For the of in those on who available website. appendix section are each is of more corporate the comprehensive more description trial our presentation interested,
there Additionally, presentation, X the timing anticipated that and data our key trials. readouts in the depict are milestones of from slides the body and of execution
the see, numerous milestones are and beyond. projected portfolio will trials clinical over from our you and next there of As data year execution
will to call I turn Dave. that, With now back the
